Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
about
Importance of Salmonella Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model.Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines.The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys.Identification of Novel Serodiagnostic Signatures of Typhoid Fever Using a Salmonella Proteome Array.Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.Induction of Cell Cycle and NK Cell Responses by Live-Attenuated Oral Vaccines against Typhoid Fever.Transcriptomics in Human Challenge Models.Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model.Causes of impaired oral vaccine efficacy in developing countries.Compositional and Functional Differences in the Human Gut Microbiome Correlate with Clinical Outcome following Infection with Wild-Type Salmonella enterica Serovar Typhi.Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic DesignAdvanced model systems and tools for basic and translational human immunology
P2860
Q37675513-84B24236-4C80-487F-AD7D-F9B0C45795CDQ38600784-90475C8E-CCCA-4B4E-8437-8111DA2630FCQ38695279-BD124F4C-CF8C-4BD9-BC18-D6010C70FD25Q41928306-18059B79-C193-4DDC-B169-99124DB8EC4BQ41928494-85303F43-6C27-494A-A2B2-95447751EEB1Q42694618-AE2B9A8F-D24F-41A3-A9F5-74D8BA4CF8B2Q47400686-1FBD0511-3785-49A8-9E52-E6AEACD64C3DQ47701060-4D4608A4-7256-4800-AF9D-B7CF653CC482Q47794110-EB530D7D-6F2B-41B7-91B1-C931364801CBQ54217774-E0994664-DC08-4EC3-952F-41D516FFAF51Q55278055-6EAC377F-48C4-48E0-B971-101281ABE562Q57946303-88219D4D-5C8E-455B-B968-5A6BD5BD840DQ59126043-EC1EDD30-466C-40FD-ADE7-FC669B0348B3
P2860
Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Using a Human Challenge Model ...... 01ZH09 with Placebo and Ty21a.
@ast
Using a Human Challenge Model ...... 01ZH09 with Placebo and Ty21a.
@en
type
label
Using a Human Challenge Model ...... 01ZH09 with Placebo and Ty21a.
@ast
Using a Human Challenge Model ...... 01ZH09 with Placebo and Ty21a.
@en
prefLabel
Using a Human Challenge Model ...... 01ZH09 with Placebo and Ty21a.
@ast
Using a Human Challenge Model ...... 01ZH09 with Placebo and Ty21a.
@en
P2093
P2860
P50
P1476
Using a Human Challenge Model ...... M01ZH09 with Placebo and Ty21a
@en
P2093
Andrew J Pollard
Anna Peters
Brian Angus
Catherine A Jeppesen
Christoph J Blohmke
Claire Jones
Claire S Waddington
Gordon Dougan
Kathryn Haworth
Liqing Zhou
P2860
P304
P356
10.1371/JOURNAL.PNTD.0004926
P407
P50
P577
2016-08-17T00:00:00Z